The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Relugolix–estradiol–norethisterone (relugolix combination therapy [CT]; Ryeqo, Gedeon Richter) is indicated 'in adult women of reproductive age for symptomatic treatment of endometriosis in women with ...

The new tablet, called relugolix-estradiol-norethisterone, has been approved by the drug regulator, National Institute for Health and Care Excellence (Nice). The ‘first-of-a-kind’ treatment ...